Form D · Biotechnology

Cara Therapeutics, Inc.

Shelton, CT · CIK 0001346830

Offering snapshot reported Dec 11, 2014 · SEC filing

Reported sold
$100K
Offering amount: $100K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 1, 2014
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 11, 2014Initial$100,003No comparison1SEC filing
Jul 21, 2010Initial$4,784,568No comparison12SEC filing
Jul 16, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Dec 12, 2006PaperNot reportedNo comparisonNot reportedSEC filing
Dec 6, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-229948

Source: Form D, filed Dec 11, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Harrison Bains Director
Derek Chalmers Director, Executive
Ed Hurwitz Director
Jeffrey L. Ives Director
Jeffrey M. Jonas Director
Michael E. Lewis Executive
Frederique Menzaghi Executive
Christopher Moller Director
Stephen Reeders Director
Josef Schoell Executive
Dean Slagel Director
Joseph W. Stauffer Executive
Martin Vogelbaum Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
One Parrott Drive
Shelton, CT, 06484